# Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

> **NCT00817284** · PHASE2 · COMPLETED · sponsor: **Ulrik Lassen** · enrollment: 60 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** bevacizumab and Irinotecan and radiotherapy
- **DRUG:** Bevacizumab and Temozolomide and radiotherapy

## Key facts

- **NCT ID:** NCT00817284
- **Lead sponsor:** Ulrik Lassen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00817284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00817284, "Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00817284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*